bioAffinity Technologies, Inc. (BIAFW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

bioAffinity Technologies, Inc. (BIAFW) Healthcare & Pipeline Overview

bioAffinity Technologies, Inc. is a development-stage company specializing in non-invasive, early-stage cancer diagnostics and targeted therapeutics. Their proprietary in-vitro diagnostic tests, utilizing technology that preferentially targets cancer cells, aim to address unmet needs in cancer care, positioning them within the competitive medical diagnostics sector.

What Is the Investment Thesis for BIAFW?

bioAffinity Technologies presents a high-risk, high-reward investment opportunity. The company's focus on early cancer diagnostics and targeted therapeutics addresses a significant unmet need in the healthcare market. The potential for CyPath Lung to improve early lung cancer detection rates is a key value driver. Successful completion of clinical trials and FDA approval are critical catalysts. However, as a development-stage company, bioAffinity faces significant challenges. The company's negative profit margin of -242.0% highlights its reliance on external funding. The high beta of 2.44 indicates significant volatility. The company's success depends on navigating the complex regulatory landscape and successfully commercializing its products. Investors should carefully consider the risks and uncertainties associated with investing in a development-stage biotechnology company.

Based on FMP financials and quantitative analysis

BIAFW Key Highlights

• Development-stage company focused on non-invasive, early-stage cancer diagnosis and treatment.
• Proprietary in-vitro diagnostic tests and targeted cancer therapeutics using technology that preferentially targets cancer cells.
• Gross Margin of 23.2% indicates potential for profitability as products are commercialized.
• Negative Profit Margin of -242.0% reflects ongoing R&D investments and lack of product revenue.
• Beta of 2.44 indicates higher volatility compared to the overall market.

Who Are BIAFW's Competitors?

BIAFW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIAFW's Key Strengths?

• Proprietary technology that preferentially targets cancer cells.
• Non-invasive diagnostic tests for early cancer detection.
• Strong focus on addressing unmet needs in cancer care.
• Experienced management team.

What Are BIAFW's Weaknesses?

• Development-stage company with limited revenue.
• Reliance on external funding.
• High beta indicates significant volatility.
• Limited commercialization experience.

What Could Drive BIAFW Stock Higher?

• FDA approval of CyPath Lung.
• Completion of clinical trials for targeted therapeutics.
• Expansion of strategic partnerships and collaborations.
• Publication of clinical trial results in peer-reviewed journals.

What Are the Key Risks for BIAFW?

• Financial-distress signal — its Altman Z-Score of -17.88 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory delays or rejection of CyPath Lung.
• Failure to achieve positive clinical trial results for targeted therapeutics.
• Competition from established players in the diagnostics and therapeutics markets.
• Inability to secure sufficient funding to support operations.

What Are the Growth Opportunities for BIAFW?

• Expansion of CyPath Lung: bioAffinity can expand the market reach of CyPath Lung beyond its initial target market. This includes targeting high-risk populations, such as smokers and individuals with a family history of lung cancer. Timeline: Ongoing, with potential for accelerated growth following successful commercialization.
• Development of Additional Diagnostic Tests: bioAffinity can leverage its proprietary technology to develop diagnostic tests for other types of cancer. This would diversify the company's product portfolio and expand its addressable market. The global cancer diagnostics market is projected to reach $35 billion by 2027. Timeline: 3-5 years, contingent on R&D and clinical trial success.
• Commercialization of Targeted Therapeutics: bioAffinity's targeted cancer therapeutics represent a significant growth opportunity. Successful development and commercialization of these therapeutics would transform the company from a diagnostics provider to a fully integrated oncology company. The market for targeted cancer therapies is estimated to be worth over $100 billion. Timeline: 5-7 years, dependent on clinical trial outcomes and regulatory approvals.
• Strategic Partnerships and Collaborations: bioAffinity can accelerate its growth through strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers. These partnerships can provide access to funding, expertise, and distribution channels. Timeline: Ongoing, with potential for near-term impact.
• International Expansion: bioAffinity can expand its operations into international markets, particularly in Europe and Asia. This would significantly increase the company's addressable market and revenue potential. International expansion requires navigating different regulatory environments and establishing local partnerships. Timeline: 3-5 years, following successful commercialization in the United States.

What Opportunities Does BIAFW Have?

• Expansion of CyPath Lung market reach.
• Development of additional diagnostic tests for other types of cancer.
• Commercialization of targeted therapeutics.
• Strategic partnerships and collaborations.

What Threats Does BIAFW Face?

• Regulatory hurdles and delays.
• Competition from established players in the diagnostics and therapeutics markets.
• Failure to achieve positive clinical trial results.
• Inability to secure sufficient funding.

What Are BIAFW's Competitive Advantages?

• Proprietary Technology: bioAffinity's technology preferentially targets cancer cells, providing a competitive advantage.
• Non-Invasive Diagnostics: Their non-invasive diagnostic tests offer a more convenient and patient-friendly alternative to traditional methods.
• Early-Stage Detection: Focus on early-stage cancer detection allows for earlier intervention and improved patient outcomes.
• Intellectual Property: Patents and other intellectual property protect their technology and products.

What Does BIAFW Do?

bioAffinity Technologies, Inc., founded on March 26, 2014, and headquartered in San Antonio, TX, is a development-stage company focused on revolutionizing cancer diagnostics and therapeutics. The company addresses the critical need for non-invasive, early-stage cancer detection and treatment. bioAffinity's core business revolves around the development of proprietary in-vitro diagnostic tests and targeted cancer therapeutics. Their innovative technology preferentially targets cancer cells, potentially leading to more effective and less harmful treatments. The company's initial focus is on early lung cancer detection with its lead product, CyPath Lung, a non-invasive test using flow cytometry to analyze patient-collected sputum samples. This test aims to identify early-stage lung cancer, enabling earlier intervention and improved patient outcomes. bioAffinity is also developing targeted cancer therapeutics that leverage the same technology used in its diagnostic tests. These therapeutics are designed to selectively target and destroy cancer cells while minimizing damage to healthy tissue. As a development-stage company, bioAffinity Technologies is currently focused on clinical trials, regulatory approvals, and commercialization of its products. The company's success hinges on the positive outcomes of its clinical trials and its ability to secure regulatory clearance from bodies such as the FDA. bioAffinity Technologies operates primarily in the United States, with potential for future expansion into international markets as its products gain regulatory approval and market acceptance.

What Products and Services Does BIAFW Offer?

• Develop non-invasive diagnostic tests for early cancer detection.
• Create targeted cancer therapeutics using proprietary technology.
• Focus on addressing unmet needs in cancer diagnosis and treatment.
• Utilize technology that preferentially targets cancer cells.
• Offer CyPath Lung, a non-invasive test for early lung cancer detection.
• Conduct clinical trials to validate the efficacy of their products.

How Does BIAFW Make Money?

• Develop and commercialize in-vitro diagnostic tests.
• Develop and commercialize targeted cancer therapeutics.
• Generate revenue through sales of diagnostic tests and therapeutics.
• Seek partnerships and collaborations for research and development.

What Industry Does BIAFW Operate In?

bioAffinity Technologies operates within the medical diagnostics and research industry, a sector experiencing significant growth driven by advancements in technology and an increasing focus on early disease detection. The market for cancer diagnostics is particularly large, with a growing demand for non-invasive and accurate diagnostic tools. bioAffinity's focus on early-stage cancer detection aligns with this trend. The competitive landscape includes established players like BTAI and emerging companies focused on innovative diagnostic solutions. Success in this industry requires strong research and development capabilities, successful clinical trials, and regulatory approvals.

Who Are BIAFW's Key Customers?

• Hospitals and clinics.
• Oncologists and pulmonologists.
• Patients at risk for cancer.
• Research institutions.

bioAffinity Technologies, Inc. (BIAFW) Valuation Context

Valued at $3.19M, BIAFW is classified as a micro-cap stock. Relative to its peer group, BIAFW's quantitative score of 50/100 is roughly in line with the peer average of 41/100.

BIAFW Revenue & Earnings Trend

In Q1 2026, BIAFW generated $1.4M in top-line revenue, marking a sequential decrease of 15.1%. The company recorded a net loss of $3.6M, with diluted EPS of $-0.81. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BIAFW averaged $-3.11 in diluted EPS.

Company Profile

bioAffinity Technologies, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Antonio, US. The company is led by CEO Maria Zannes. BIAFW has traded publicly since 2022.

F-Score 3/9Financial Health

bioAffinity Technologies, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.88 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project bioAffinity Technologies, Inc. revenue of about $7.3M for fiscal 2026, with EPS near $-8.10.

BIAFW Financials

BIAFW Latest News

BIAFW Analyst Consensus

BIAFW MoonshotScore

bioAffinity Technologies, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources